Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kavita Subramaniam

Kavita Subramaniam

Translational Research Manager

I joined the Translational Research Office (TRO) as a Translational Research Manager in January 2023.

Prior to joining the TRO, I did my postdoctoral work with King's College London. The team and I worked on a translational gene therapy project called ‘SPRAYCOL’ to develop a new form of gene supplementation therapy for individuals suffering from a rare genetic skin disease - recessive dystrophic epidermolysis bullosa (RDEB). We were testing a patient-friendly, less-invasive gene therapy approach and a delivery system using a novel cell spray device to minimize patients' pain in collaboration with a biotechnology company, RenovaCare Inc. 

Before that, I did a postdoctoral project with the University of Oxford where I worked alongside Bayer Pharmaceuticals, as part of the Oxford-Bayer Alliance. We worked on a target discovery project on the role of vasculature in uterine fibroid-related heavy menstrual bleeding.

I did my PhD at the University of Malaya, Malaysia on the role of tumour microenvironment in endometrial cancer.